Aicaigou LogoB2B Wiki

Major Autohemotherapy Equipment

Updated: 2026-08-12

Overview

Major Autohemotherapy Devices are specialized medical systems designed for extracorporeal blood treatment with medical ozone. Developed in Germany during the 1970s, these devices combine phlebotomy equipment with gas mixing technology to create precise ozone-blood concentrations. Modern iterations integrate touchscreen controls, automated safety checks, and disposable blood circuits to minimize contamination risks. Used predominantly in integrative medicine clinics and wellness centers, MAH devices require operators with hematology training. The therapy is contraindicated for patients with G6PD deficiency or severe anemia. Leading manufacturers include Herrmann Apparatebau (Germany) and Zotzmann + Stahl (Austria), with Asian brands gaining market share through cost-competitive models.

Structure and Working Principle

The device comprises three core subsystems: a blood withdrawal module with peristaltic pump (typically 50-100mL/min flow rate), an ozone generator producing 5-80μg/mL concentrations, and a gas-blood mixing chamber with 5-10 minute incubation time. Advanced models feature heparin-coated circuits and pressure sensors to prevent coagulation or vein collapse. Operation follows a closed-cycle process: venous blood is drawn into a sterile container, mixed with pre-set ozone doses, then returned via the same IV line. The entire procedure lasts 20-45 minutes. Some systems incorporate UV irradiation or laser oxygenation for enhanced therapeutic effects. Critical components must withstand autoclaving at 121°C for sterilization.

Key Features

Medical-grade ozone generators in MAH devices maintain ±5% concentration accuracy, crucial for therapeutic efficacy and safety. Dual-wavelength spectrophotometers verify ozone levels in real-time, while fail-safe mechanisms halt operation if parameters deviate beyond preset limits (e.g., blood flow <40mL/min). Ergonomic designs prioritize single-handed operation with foot pedal controls for phlebotomy. Modular configurations allow integration with EHR systems for treatment documentation. High-end models offer customizable protocols for different indications – lower concentrations (20-30μg/mL) for immune stimulation versus higher doses (50-70μg/mL) for antimicrobial applications.

Application Areas

Clinical applications focus on chronic conditions resistant to conventional treatments. Rheumatology accounts for 38% of MAH usage (osteoarthritis, fibromyalgia), followed by metabolic disorders (diabetic foot ulcers) at 25% and neurology (multiple sclerosis) at 18%. Emerging research explores applications in Lyme disease and long COVID management. In aesthetic medicine, MAH demonstrates efficacy in reducing inflammatory markers associated with skin aging. Veterinary applications are growing, particularly for equine joint diseases. Treatment frequency varies from 2-3 sessions weekly for acute conditions to monthly maintenance protocols, with noticeable effects typically appearing after 5-8 sessions.

Maintenance and Precautions

Daily maintenance includes circuit integrity checks and calibration of gas sensors using NIST-traceable standards. Monthly servicing should verify pump accuracy (±2% tolerance) and replace ozone-resistant seals. Manufacturers recommend annual factory recalibration, especially for the UV ozone destruct system preventing environmental release. Critical precautions include: never exceeding 200mL blood volume per session, maintaining <5°C coolant temperature for ozone generators, and using only medical-grade oxygen (99.995% purity). Clinics must establish emergency protocols for rare but serious complications like air embolism (incidence <0.01%). Staff training should cover both device operation and recognition of hemolytic reactions.

B2B Procurement Guide

Medical institutions should prioritize suppliers with ISO 13485 certification and at least 5 years of MAH-specific manufacturing experience. Key evaluation criteria include: availability of disposable kits (costing $50-120 per treatment), service response time (<48 hours), and compatibility with existing anticoagulants (e.g., heparin vs. citrate). Total cost of ownership analysis should factor in ozone generator lifespan (typically 5,000 hours) and power consumption (200-500W). Leasing options are available from European manufacturers at approximately $1,200-$3,000 monthly. Emerging markets may consider Chinese OEM models (30-40% cheaper) but must verify CFDA certification and local service support.

Related Manufacturers